Selected research
Industry Research
Glycopeptide Antibiotics Industry Research Report 2026
Market perspective
The global Glycopeptide Antibiotics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Glycopeptide Antibiotics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Glycopeptide Antibiotics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Glycopeptide Antibiotics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Glycopeptide Antibiotics include Allergan, Alvogen, ANI Pharmaceuticals, Aurobindo Pharma, Hikma Pharmaceuticals plc, Lytix Biopharma, Theravance Biopharma, Eli Lilly and Company and Shenwei Pharmaceutical and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Glycopeptide Antibiotics market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Glycopeptide Antibiotics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Glycopeptide Antibiotics Market by Company
Allergan
Alvogen
ANI Pharmaceuticals
Aurobindo Pharma
Hikma Pharmaceuticals plc
Lytix Biopharma
Theravance Biopharma
Eli Lilly and Company
Shenwei Pharmaceutical
Zhejiang Hisun Pharmaceutical Co., Ltd.
Glycopeptide Antibiotics Segment by Type
Vancomycin
Teicoplanin
Bleomycin
Glycopeptide Antibiotics Segment by Application
Enterococcus Treatment
Staphylococcus Aureus Treatment
Glycopeptide Antibiotics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glycopeptide Antibiotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glycopeptide Antibiotics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glycopeptide Antibiotics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Glycopeptide Antibiotics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vancomycin
- Teicoplanin
- Bleomycin
Applications
- Enterococcus Treatment
- Staphylococcus Aureus Treatment
Companies covered
- Allergan
- Alvogen
- ANI Pharmaceuticals
- Aurobindo Pharma
- Hikma Pharmaceuticals plc
- Lytix Biopharma
- Theravance Biopharma
- Eli Lilly and Company
- Shenwei Pharmaceutical
- Zhejiang Hisun Pharmaceutical Co., Ltd.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Glycopeptide Antibiotics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Vancomycin
- 2.2.3 Teicoplanin
- 2.2.4 Bleomycin
- 2.3 Glycopeptide Antibiotics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Enterococcus Treatment
- 2.3.3 Staphylococcus Aureus Treatment
- 2.4 Assumptions and Limitations
3 Glycopeptide Antibiotics Breakdown Data by Type
- 3.1 Global Glycopeptide Antibiotics Historic Market Size by Type (2021-2026)
- 3.2 Global Glycopeptide Antibiotics Forecasted Market Size by Type (2027-2032)
4 Glycopeptide Antibiotics Breakdown Data by Application
- 4.1 Global Glycopeptide Antibiotics Historic Market Size by Application (2021-2026)
- 4.2 Global Glycopeptide Antibiotics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Glycopeptide Antibiotics Market Perspective (2021-2032)
- 5.2 Global Glycopeptide Antibiotics Growth Trends by Region
- 5.2.1 Global Glycopeptide Antibiotics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Glycopeptide Antibiotics Historic Market Size by Region (2021-2026)
- 5.2.3 Glycopeptide Antibiotics Forecasted Market Size by Region (2027-2032)
- 5.3 Glycopeptide Antibiotics Market Dynamics
- 5.3.1 Glycopeptide Antibiotics Industry Trends
- 5.3.2 Glycopeptide Antibiotics Market Drivers
- 5.3.3 Glycopeptide Antibiotics Market Challenges
- 5.3.4 Glycopeptide Antibiotics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Glycopeptide Antibiotics Players by Revenue
- 6.1.1 Global Top Glycopeptide Antibiotics Players by Revenue (2021-2026)
- 6.1.2 Global Glycopeptide Antibiotics Revenue Market Share by Players (2021-2026)
- 6.2 Global Glycopeptide Antibiotics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Glycopeptide Antibiotics Head Office and Area Served
- 6.4 Global Glycopeptide Antibiotics Players, Product Type & Application
- 6.5 Global Glycopeptide Antibiotics Manufacturers Established Date
- 6.6 Global Glycopeptide Antibiotics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Glycopeptide Antibiotics Market Size (2021-2032)
- 7.2 North America Glycopeptide Antibiotics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Glycopeptide Antibiotics Market Size by Country (2021-2026)
- 7.4 North America Glycopeptide Antibiotics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Glycopeptide Antibiotics Market Size (2021-2032)
- 8.2 Europe Glycopeptide Antibiotics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Glycopeptide Antibiotics Market Size by Country (2021-2026)
- 8.4 Europe Glycopeptide Antibiotics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Glycopeptide Antibiotics Market Size (2021-2032)
- 9.2 Asia-Pacific Glycopeptide Antibiotics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Glycopeptide Antibiotics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Glycopeptide Antibiotics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Glycopeptide Antibiotics Market Size (2021-2032)
- 10.2 South America Glycopeptide Antibiotics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Glycopeptide Antibiotics Market Size by Country (2021-2026)
- 10.4 South America Glycopeptide Antibiotics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Glycopeptide Antibiotics Market Size (2021-2032)
- 11.2 Middle East & Africa Glycopeptide Antibiotics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Glycopeptide Antibiotics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Glycopeptide Antibiotics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Allergan
- 12.1.1 Allergan Company Information
- 12.1.2 Allergan Business Overview
- 12.1.3 Allergan Revenue in Glycopeptide Antibiotics Business (2021-2026)
- 12.1.4 Allergan Glycopeptide Antibiotics Product Portfolio
- 12.1.5 Allergan Recent Developments
- 12.2 Alvogen
- 12.2.1 Alvogen Company Information
- 12.2.2 Alvogen Business Overview
- 12.2.3 Alvogen Revenue in Glycopeptide Antibiotics Business (2021-2026)
- 12.2.4 Alvogen Glycopeptide Antibiotics Product Portfolio
- 12.2.5 Alvogen Recent Developments
- 12.3 ANI Pharmaceuticals
- 12.3.1 ANI Pharmaceuticals Company Information
- 12.3.2 ANI Pharmaceuticals Business Overview
- 12.3.3 ANI Pharmaceuticals Revenue in Glycopeptide Antibiotics Business (2021-2026)
- 12.3.4 ANI Pharmaceuticals Glycopeptide Antibiotics Product Portfolio
- 12.3.5 ANI Pharmaceuticals Recent Developments
- 12.4 Aurobindo Pharma
- 12.4.1 Aurobindo Pharma Company Information
- 12.4.2 Aurobindo Pharma Business Overview
- 12.4.3 Aurobindo Pharma Revenue in Glycopeptide Antibiotics Business (2021-2026)
- 12.4.4 Aurobindo Pharma Glycopeptide Antibiotics Product Portfolio
- 12.4.5 Aurobindo Pharma Recent Developments
- 12.5 Hikma Pharmaceuticals plc
- 12.5.1 Hikma Pharmaceuticals plc Company Information
- 12.5.2 Hikma Pharmaceuticals plc Business Overview
- 12.5.3 Hikma Pharmaceuticals plc Revenue in Glycopeptide Antibiotics Business (2021-2026)
- 12.5.4 Hikma Pharmaceuticals plc Glycopeptide Antibiotics Product Portfolio
- 12.5.5 Hikma Pharmaceuticals plc Recent Developments
- 12.6 Lytix Biopharma
- 12.6.1 Lytix Biopharma Company Information
- 12.6.2 Lytix Biopharma Business Overview
- 12.6.3 Lytix Biopharma Revenue in Glycopeptide Antibiotics Business (2021-2026)
- 12.6.4 Lytix Biopharma Glycopeptide Antibiotics Product Portfolio
- 12.6.5 Lytix Biopharma Recent Developments
- 12.7 Theravance Biopharma
- 12.7.1 Theravance Biopharma Company Information
- 12.7.2 Theravance Biopharma Business Overview
- 12.7.3 Theravance Biopharma Revenue in Glycopeptide Antibiotics Business (2021-2026)
- 12.7.4 Theravance Biopharma Glycopeptide Antibiotics Product Portfolio
- 12.7.5 Theravance Biopharma Recent Developments
- 12.8 Eli Lilly and Company
- 12.8.1 Eli Lilly and Company Company Information
- 12.8.2 Eli Lilly and Company Business Overview
- 12.8.3 Eli Lilly and Company Revenue in Glycopeptide Antibiotics Business (2021-2026)
- 12.8.4 Eli Lilly and Company Glycopeptide Antibiotics Product Portfolio
- 12.8.5 Eli Lilly and Company Recent Developments
- 12.9 Shenwei Pharmaceutical
- 12.9.1 Shenwei Pharmaceutical Company Information
- 12.9.2 Shenwei Pharmaceutical Business Overview
- 12.9.3 Shenwei Pharmaceutical Revenue in Glycopeptide Antibiotics Business (2021-2026)
- 12.9.4 Shenwei Pharmaceutical Glycopeptide Antibiotics Product Portfolio
- 12.9.5 Shenwei Pharmaceutical Recent Developments
- 12.10 Zhejiang Hisun Pharmaceutical Co., Ltd.
- 12.10.1 Zhejiang Hisun Pharmaceutical Co., Ltd. Company Information
- 12.10.2 Zhejiang Hisun Pharmaceutical Co., Ltd. Business Overview
- 12.10.3 Zhejiang Hisun Pharmaceutical Co., Ltd. Revenue in Glycopeptide Antibiotics Business (2021-2026)
- 12.10.4 Zhejiang Hisun Pharmaceutical Co., Ltd. Glycopeptide Antibiotics Product Portfolio
- 12.10.5 Zhejiang Hisun Pharmaceutical Co., Ltd. Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst